[18F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET.
Peipei Wang, Sun Yu, Xiaorui Chen...
https://pubmed.ncbi.nlm.nih.gov/40717185Actively Recruiting
Early Phase 1
Age: 1Year - 80Years
All Genders
ID05069220
A Study of 18F-MFBG Imaging for Tumor Burden and Diagnostic Performance in Pheochromocytoma, Paraganglioma, and Neuroblastoma
Led by Peking Union Medical College Hospital · Updated on 2024-03-01
150
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the use of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) to evaluate neuroendocrine tumors, mainly pheochromocytoma, paraganglioma (PPGL), and neuroblastoma (NB). These tumors express norepinephrine transporter (NET), which is targeted by imaging substances like 123I/131I-MIBG. However, current imaging methods have limitations such as low resolution and long waiting times, which affect diagnosis. This study aims to assess the safety, image quality, diagnostic accuracy, and tumor burden detection of 18F-MFBG PET in these neural crest tumors.
CONDITIONS
Brief Title
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Who Can Participate
Age: 1Year - 80Years
All Genders
Eligibility Criteria
You may qualify if you...
- The participant has read, signed, and dated an informed consent form before any study procedures.
- Patients have histologically confirmed or clinically suspected neural crest tumor.
- Neuroblastoma patients should have routine 123I-MIBG scintigraphy (planar + SPECT/CT) within 6 months before or scheduled within 3 months after the inclusion visit.
- Participants can be male or nonpregnant, nonlactating females who are surgically sterile or post-menopausal.
- Participants must be able and willing to comply with all study procedures as described in the protocol.
You will not qualify if you...
- Patients who are potentially pregnant or breastfeeding.
- Patients who undergo surgery between selection and inclusion visits.
- Patients who are pregnant, may become pregnant, or wish to become pregnant during the study period.
- Patients not suitable for trial participation according to researchers.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Single day
Participants receive a single intravenous injection of 18F-MFBG followed by a PET/CT scan 60 minutes after injection. Some participants may also receive 68Ga-DOTATATE PET/CT scans for comparison. Neuroblastoma patients should have routine 123I-MIBG scintigraphy performed within 6 months before or within 3 months after this visit.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 2 years
Participants are observed to evaluate the diagnostic performance and lesion targeting of 18F-MFBG PET over an average of 1 to 2 years.
Follow-up visits as per clinical standard
Trial Site Locations
Total: 1 location
1
Peking union medical college hospital
Beijing, Dongcheng, China, 100010
Actively Recruiting
Loading map...
Research Team
P
Peipei Wang
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
[18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma.
Peipei Wang, Tuo Li, Zhikai Liu...
https://pubmed.ncbi.nlm.nih.gov/37160439